Nelistotug

DB19334InvestigationalProtein Based Therapies

Nelistotug is under investigation in clinical trial NCT06062420 (A Platform Study of Novel Immunotherapy Combinations as First-line Treatment in Participants With PD-L1 Positive Recurrent/metastatic Squamous Cell Carcinoma of the Head...

Mechanism: Pharmacologically active on T-cell surface protein tactile
Curator reviewed
Also known as: Gamma1 heavy chain Homo sapiens (1-452) [VH(Homo sapiens IGHV1-69*01 (95.9%) -(IGHD)-IGHJ1*01 (90.9%) L123>T (117), CDR-IMGT [8.8.15](26-33.51-58.97-111)) (1-122) -Homo sapiens IGHG1*01 (100%), G1m17,1 CH1 K120, CH3 D12, L14 (CH1 K120 (219) (123-220), hi · Immunoglobulin G1, anti-(human CD96 antigen) (human monoclonal GSK6097608 γ1-chain), disulfide with human monoclonal GSK6097608 κ-chain, dimer · Nelistotug (immunoglobulin G1-kappa, anti-[Homo sapiens CD96 (T cell activation increased late expression, TACTILE, T-cell surface protein tactile)], Homo sapiens monoclonal antibody)
Code names: GSK-6097608

Resolves to

Compound

UNII7MCC43O1YBCAS2645437-82-5

Targets

P40200CD96

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Nelistotug, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account